

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended		Twelve Months Ended	
	December 31, 2008		December 31, 2008	
	International	Total	International	Total
	Net Sales	Net Sales	Net Sales	Net Sales
Net sales, as reported	\$ 45,270	\$ 120,109	\$ 183,466	\$ 465,547
Currency impact as compared to prior period	1,994	1,994	(7,872)	(7,872)
Net sales, excluding the impact of foreign currency	<u>\$ 47,264</u>	<u>\$ 122,103</u>	<u>\$ 175,594</u>	<u>\$ 457,675</u>

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Twelve Months Ended	
	December 31, 2008	December 31, 2007	December 31, 2008	December 31, 2007
Operating Income				
Operating income (loss), as reported	\$ 10,027	\$ 1,973	\$ 22,413	\$ 1,454
<i>Reconciling items impacting Gross Profit:</i>				
Cost of Sales – restructuring	-	2,139	-	2,139
Inventory step-up amortization	18	109	113	418
Non-cash, stock-based compensation	292	483	1,244	2,046
Total	<u>310</u>	<u>2,731</u>	<u>1,357</u>	<u>4,603</u>
<i>Reconciling items impacting Selling, General and Administrative expenses:</i>				
Arbitration judgment	-	3,269	-	3,269
Non-cash, stock-based compensation	2,204	3,231	10,644	12,061
U.S. governmental inquiries	2,916	-	7,648	-
Appellate court decision	-	-	2,346	-
Total	<u>5,120</u>	<u>6,500</u>	<u>20,638</u>	<u>15,330</u>
<i>Reconciling items impacting Research and Development expenses:</i>				
Non-cash, stock-based compensation	517	409	1,613	2,425
<i>Other Reconciling Items:</i>				
Restructuring charges	1,110	2,229	6,705	16,734
Acquired in-process research and development	-	-	2,490	-
Total	<u>1,110</u>	<u>2,229</u>	<u>9,195</u>	<u>16,734</u>
Operating income, as adjusted	<u>\$ 17,084</u>	<u>\$ 13,842</u>	<u>\$ 55,216</u>	<u>\$ 40,546</u>
Operating income, as adjusted, as a percentage of net sales	<u>14.2%</u>	<u>13.4%</u>	<u>11.9%</u>	<u>10.5%</u>

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended		Twelve Months Ended	
	December 31, 2008	December 31, 2007	December 31, 2008	December 31, 2007
Net Income				
Net (loss) income, as reported	\$ (2,691)	\$ 1,384	\$ 3,197	\$ 961
<i>Pre-tax impact of reconciling items:</i>				
Non-cash, stock-based compensation	3,013	4,123	13,501	16,532
Restructuring charges	1,110	4,368	6,705	18,873
Arbitration judgment (including interest)	-	3,934	-	3,934
Inventory step-up amortization	18	109	113	418
U.S. governmental inquiries	2,916	-	7,648	-
Appellate court decision (including interest)	-	-	2,638	-
Acquired in-process research and development	-	-	2,490	-
Total	<u>7,057</u>	<u>12,534</u>	<u>33,095</u>	<u>39,757</u>
<i>Tax effect of reconciling items:</i>				
Non-cash, stock-based compensation	(576)	(670)	(3,674)	(3,665)
Restructuring charges	(1,275)	(1,531)	(3,451)	(6,416)
Arbitration judgment	-	(1,550)	-	(1,550)
Inventory step-up amortization	(7)	(44)	(44)	(165)
United States governmental inquiries	(1,122)	-	(2,987)	-
Appellate court decision	-	-	(1,030)	-
Acquired in-process research and development	-	-	-	-
Valuation allowance for French NOL's	11,223	-	11,223	-
Total	<u>8,243</u>	<u>(3,795)</u>	<u>37</u>	<u>(11,796)</u>
Net income, as adjusted	<u>\$ 12,609</u>	<u>\$ 10,123</u>	<u>\$ 36,329</u>	<u>\$ 28,922</u>

	Three Months Ended		Three Months Ended	
	December 31, 2008		December 31, 2007	
	As Reported	As Adjusted	As Reported	As Adjusted
Basic net (loss) income	\$ (2,691)	\$ 12,609	\$ 1,384	\$ 10,123
Interest expense on convertible notes	N/A	935	N/A	337
Diluted net (loss) income	\$ (2,691)	\$ 13,544	\$ 1,384	\$ 10,460
Basic shares	37,198	37,198	36,317	36,317
Dilutive effect of stock options and restricted shares	-	198	747	747
Dilutive effect of convertible notes	-	6,126	N/A	2,189
Diluted shares	37,198	43,522	37,064	39,253
Net (loss) income per share, diluted	<u>\$ (0.07)</u>	<u>\$ 0.31</u>	<u>\$ 0.04</u>	<u>\$ 0.27</u>

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	<u>Twelve Months Ended</u>		<u>Twelve Months Ended</u>	
	<u>December 31, 2008</u>		<u>December 31, 2007</u>	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
Basic net income	\$ 3,197	\$ 36,329	\$ 961	\$ 28,922
Interest expense on convertible notes	N/A	3,741	N/A	337
Diluted net income	\$ 3,197	\$ 40,070	\$ 961	\$ 29,259
Basic shares	36,933	36,933	35,812	35,812
Dilutive effect of stock options and restricted shares	468	468	671	671
Dilutive effect of convertible notes	-	6,126	N/A	552
Diluted shares	37,401	43,527	36,483	37,035
Net income per share, diluted	<u>\$ 0.09</u>	<u>\$ 0.92</u>	<u>\$ 0.03</u>	<u>\$ 0.79</u>

	<u>Three Months Ended</u>		<u>Twelve Months Ended</u>	
	<u>December 31, 2008</u>	<u>December 31, 2007</u>	<u>December 31, 2008</u>	<u>December 31, 2007</u>
	Net Income per Diluted Share			
Net (loss) income, as reported, per diluted share	\$ (0.07)	\$ 0.04	\$ 0.09	\$ 0.03
Interest expense on convertible notes	0.02	0.01	0.09	0.01
Dilutive effect of convertible notes	0.01	0.00	(0.01)	0.00
Non-cash, stock-based compensation	0.06	0.09	0.23	0.35
Restructuring charges	0.00	0.08	0.07	0.34
Arbitration judgment (including interest)	-	0.06	-	0.07
Inventory step-up amortization	-	0.00	0.00	0.00
U.S. governmental inquiries	0.04	-	0.11	-
Appellate court decision	-	-	0.04	-
Acquired in-process research and development	-	-	0.06	-
Valuation allowance for French NOL's	0.26	-	0.26	-
Net income, as adjusted, per diluted share	<u>\$ 0.31</u>	<u>\$ 0.27</u>	<u>\$ 0.92</u>	<u>\$ 0.79</u>

Wright Medical Group, Inc.
Reconciliation of Effective Tax Rate, As Reported, to Effective Tax Rate, As Adjusted
(unaudited)

	<u>Three Months Ended</u>		<u>Twelve Months Ended</u>	
	<u>December 31, 2008</u>	<u>December 31, 2007</u>	<u>December 31, 2008</u>	<u>December 31, 2007</u>
	Effective tax rate, as reported	128.6%	9.6%	85.2%
Non-cash, stock-based expense	(1.0%)	(4.9%)	(2.1%)	(5.9%)
Restructuring charges	11.2%	18.8%	4.3%	(22.1%)
Arbitration judgment (including interest)	-	4.4%	-	0.4%
Inventory step-up amortization	0.0%	0.1%	0.0%	0.1%
U.S. governmental inquiries	3.9%	-	0.8%	-
Appellate court decision	-	-	0.4%	-
Acquired in-process research and development	-	-	(3.1%)	-
Valuation allowance for French NOL's	(119.3%)	-	(52.0%)	-
Effective tax rate, as adjusted	<u>23.4%</u>	<u>28.0%</u>	<u>33.5%</u>	<u>31.3%</u>